Recently, global pharmaceutical giant Eli Lilly released new clinical trial data for its novel weight-loss drug, Retatrutide, drawing significant attention from the medical community and the public. Retatrutide is a triple agonist that simultaneously targets three receptors: GLP-1, GIP, and glucagon, aiming to more comprehensively regulate appetite, energy expenditure, and metabolism. In a 24-week Phase II clinical trial, obese patients receiving the highest dose (12 mg) lost an average of 24.2% of their body weight, with some participants losing over 30%. These results significantly outperform current leading GLP-1-based therapies like semaglutide. Eli Lilly stated that Retatrutide has the potential to become a next-generation, highly effective weight-loss treatment and is now advancing into Phase III trials. Experts caution that while the efficacy is promising, long-term safety, side effects, and appropriate patient populations still require further evaluation. If ultimately approved, this drug could reshape the landscape of obesity treatment and offer new hope to hundreds of millions of people living with overweight or obesity.
近日，全球知名制药公司礼来（Eli Lilly）公布了其新型减肥药物Retatrutide的最新临床试验数据，引发医学界和公众广泛关注。该药物是一种三重激动剂，可同时作用于GLP-1、GIP和胰高血糖素三种受体，旨在更全面地调节食欲、能量消耗与代谢。在为期24周的II期临床试验中，接受最高剂量（12毫克）治疗的肥胖患者平均体重减轻了24.2%，部分参与者减重幅度甚至超过30%。这一结果显著优于目前市场上主流的GLP-1类药物如司美格鲁肽（Semaglutide）。礼来表示，Retatrutide有望成为新一代高效减重疗法，目前已进入III期临床试验阶段。专家指出，尽管疗效令人鼓舞，但长期安全性、副作用及适用人群仍需进一步验证。若最终获批，该药或将重塑肥胖治疗格局，并为数亿超重或肥胖患者带来新希望。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/2414.html